NASDAQ:AXLA Axcella Health (AXLA) Stock Price, News & Analysis → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free AXLA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.36▼$0.5150-Day Range$0.40▼$4.5852-Week Range$0.34▼$41.25Volume6,700 shsAverage Volume267,009 shsMarket Capitalization$1.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Axcella Health alerts: Email Address Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Axcella Health Stock (NASDAQ:AXLA)Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.Read More Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… AXLA Stock News HeadlinesDecember 27, 2023 | bizjournals.comBiotech layoffs 2023: In Q4, 11 companies laid off around 500 peopleDecember 25, 2023 | bizjournals.comYear in Review: Here are the top stories in Boston-area life sciences in 2023March 28, 2024 | DTI (Ad)my top trade on these 9 tickersThis indicator is uniquely designed to spot the most significant moves in the top stocks out there (and according to our backtesting it has historically nailed these moves with a stunning 90% accuracy). Now, most folks have been saying NVDA is way overbought or overpriced. They didn’t want to “buy at the top” 6 weeks ago… Or again 4 weeks ago… or again 2 weeks ago… And it’s not their fault! That’s what all the talking heads were saying too. But the Apex Indicator would have clearly shown that these were opportunities to buy. And, sure enough, Nvidia slammed through the recommended targets again and again.December 5, 2023 | msn.comAxcella Health to closeDecember 5, 2023 | bizjournals.comFlagship spinout Axcella collapses, leaving future of its long Covid drug uncertainNovember 7, 2023 | morningstar.comAxcella Health Inc AXLANovember 1, 2023 | msn.comAxcella Health (AXLA) Price Target Increased by 7971.00% to 15,870.09September 29, 2023 | markets.businessinsider.comPre-market Movers: RLMD, BROG, VSME, AXLA, NKE…March 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…September 15, 2023 | finance.yahoo.comAre Medical Stocks Lagging Axcella Health (AXLA) This Year?September 15, 2023 | finance.yahoo.comAre Medical Stocks Lagging Axcella Health (AXLA) This Year?September 15, 2023 | investorplace.comWhy Is Axcella Health (AXLA) Stock Down 24% Today?September 15, 2023 | msn.comFord, GM shares fall on strike action, with ARM stock jumping post IPO and other shares on the moveSeptember 14, 2023 | finance.yahoo.comAxcella Announces Reverse Stock Split Effective September 19, 2023September 5, 2023 | benzinga.comPenny Stocks Stocks Poised To Pop On News (EPAZ, AXLA, NVOS, IQST)August 30, 2023 | finance.yahoo.comAre Medical Stocks Lagging Clover Health Investments (CLOV) This Year?August 30, 2023 | benzinga.comWhat's Going On With Axcella Health Stock This Week?August 30, 2023 | finance.yahoo.comAxcella (AXLA) Up on Patent Grant for Long Covid Fatigue DrugAugust 30, 2023 | finance.yahoo.comAre Medical Stocks Lagging Clover Health Investments (CLOV) This Year?August 29, 2023 | benzinga.comAxcella Health Stock Is Skyrocketing: What's Going On?August 29, 2023 | proactiveinvestors.comAxcella Health stock rockets on long Covid patent winAugust 29, 2023 | finance.yahoo.comAxcella Granted Patent for Long COVID Fatigue TreatmentAugust 29, 2023 | investorplace.comWhy Is Axcella Health (AXLA) Stock Up 280% Today?May 8, 2023 | markets.businessinsider.comAxcella Health (AXLA) Gets a Hold from H.C. WainwrightApril 17, 2023 | finance.yahoo.comAxcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023April 14, 2023 | finance.yahoo.comBig Bank's Big Q1 Performance, Florida Gov. Quietly Slips 6-Week Abortion Ban Into Law, Subway Sandwich Seeks $10B Sale: Today's Top StoriesApril 14, 2023 | msn.comLong COVID-Fatigue Impacts 50M People - Axcella Health Seeks Funding To Support Drug DevelopmentSee More Headlines Receive AXLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axcella Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/27/2024Next Earnings (Estimated)3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AXLA CUSIPN/A CIK1633070 Webwww.axcellahealth.com Phone(857) 320-2200Fax617-441-6243Employees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($19.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,190,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-259.91% Debt Debt-to-Equity RatioN/A Current Ratio0.80 Quick Ratio0.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book0.28Miscellaneous Outstanding Shares2,950,000Free Float2,883,000Market Cap$1.18 million OptionableOptionable Beta0.46 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Craig R. Jalbert CIRA (Age 61)President, CEO, Treasurer, Secretary, Financial and Accounting Officer & Director Dr. Alison D. Schecter M.D. (Age 58)President of Strategy & Operations Comp: $525.53kMr. David R. Epstein B.Sc. (Age 61)M.B.A., Consultant Comp: $228.34kMr. Dan KirbySenior Vice President of Strategic OperationsMarie WashburnVP of Finance & Corporate ControllerDr. Karim Azer Ph.D.Vice President of Platform & DiscoveryMore ExecutivesKey CompetitorsSQZ BiotechnologiesNYSE:SQZTC BiopharmNASDAQ:TCBPScinai ImmunotherapeuticsNASDAQ:SCNIWindtree TherapeuticsNASDAQ:WINTEloxx PharmaceuticalsNASDAQ:ELOXView All Competitors AXLA Stock Analysis - Frequently Asked Questions When is Axcella Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our AXLA earnings forecast. How were Axcella Health's earnings last quarter? Axcella Health Inc. (NASDAQ:AXLA) posted its earnings results on Wednesday, November, 10th. The company reported ($10.25) EPS for the quarter, topping analysts' consensus estimates of ($11.25) by $1.00. When did Axcella Health's stock split? Axcella Health shares reverse split on Tuesday, September 19th 2023. The 1-25 reverse split was announced on Thursday, September 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What is Bill Hinshaw's approval rating as Axcella Health's CEO? 5 employees have rated Axcella Health Chief Executive Officer Bill Hinshaw on Glassdoor.com. Bill Hinshaw has an approval rating of 100% among the company's employees. This puts Bill Hinshaw in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Axcella Health to a friend. What other stocks do shareholders of Axcella Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Evofem Biosciences (EVFM), ADMA Biologics (ADMA), Coty (COTY), Energy Transfer (ET), Myovant Sciences (MYOV), NVIDIA (NVDA), Pfizer (PFE) and Moderna (MRNA). When did Axcella Health IPO? Axcella Health (AXLA) raised $76 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 3,600,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink acted as the underwriters for the IPO. Who are Axcella Health's major shareholders? Axcella Health's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David R Epstein, Des Produits Nestle S Societe, Margaret Koziel, Paul Fehlner, Robert Crane and William Hinshaw. View institutional ownership trends. This page (NASDAQ:AXLA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axcella Health Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.